Comparative Pharmacology
Head-to-head clinical analysis: QFITLIA versus ZYMFENTRA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: QFITLIA versus ZYMFENTRA.
QFITLIA vs ZYMFENTRA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
QFITLIA is a monoclonal antibody that binds to the p40 subunit of interleukin-12 (IL-12) and interleukin-23 (IL-23), inhibiting their interaction with the IL-12Rβ1 receptor and subsequent activation of cytokine signaling. This reduces inflammatory responses mediated by Th1 and Th17 pathways.
Tumor necrosis factor (TNF) alpha inhibitor; biosimilar to infliximab. Binds to soluble and membrane-bound TNF-alpha, preventing interaction with p55 and p75 TNF receptors, reducing inflammatory signaling.
300 mg intravenously once daily for 3 days, then 150 mg intravenously once daily.
120 mg subcutaneously every 2 weeks after a 40 mg intravenous loading dose at week 0.
None Documented
None Documented
12 hours; prolonged to 24 hours in moderate renal impairment (CrCl 30-50 mL/min)
Terminal elimination half-life is approximately 7.7 to 9.5 days. Clinical context: This supports a dosing interval of every 8 weeks for maintenance therapy in most indications. Patients with positive anti-drug antibodies may have accelerated clearance and reduced half-life.
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other
ZYMFENTRA (infliximab) is eliminated primarily via the reticuloendothelial system and target-mediated clearance. Fecal excretion accounts for less than 10% of the administered dose. Renal excretion is minimal (<0.1%) as intact immunoglobulin. Biliary excretion is negligible. The majority of clearance occurs through cellular internalization and catabolism.
Category C
Category C
TNF Inhibitor
TNF Inhibitor